MASH

Metabolic dysfunction-associated steatohepatitis (MASH), previously known as nonalcoholic steatohepatitis (NASH).

Liver disease
Biotech

Viking liver disease drug reduces fibrosis in final ph. 2 data

The drug reduced liver fat content by an average of 37% to 55%, with all treatment arms showing significant improvements compared to placebo.
Darren Incorvaia Nov 20, 2024 3:20pm
An arrow incrementally going up stairs before pointing straight up Blue background

Boston's monthly MASH prospect hits goal in phase 2

Nov 15, 2024 11:00am
liver

Gilead gives up on $15M MASH bet after mulling preclinical data

Oct 11, 2024 10:28am
proclaim red announcement

Aligos MASH prospect slashes liver fat in phase 2

Sep 19, 2024 1:00pm
arrow back backwards u-turn turn around reverse

Novo Nordisk axes once-monthly GLP-1/GIP agonist MASH prospect

Aug 7, 2024 7:00am
MA strategy deal block push come together form

In struggling Hepion, Israeli biotech spies path to go public

Jul 22, 2024 9:14am